David Meek is the founder of FerGene. FerGene has raised $570M in total funding. Backed by Ferring Pharmaceuticals, Blackstone Life Sciences.
David Meek transitioned from Ipsen to become the CEO of FerGene, a gene therapy spinout launched by Ferring Pharmaceuticals and Blackstone Life Sciences. He is leading the company's efforts to develop and commercialize nadofaragene firadenovec, a gene therapy for bladder cancer.
Full founder directory · Investor directory · Company funding database · Fundraising library